Predicting risk of suicidal behaviour after initiation of selective serotonin reuptake inhibitors in children, adolescents and young adults: protocol for development and validation of clinical prediction models
- PMID: 37612105
- PMCID: PMC10450049
- DOI: 10.1136/bmjopen-2023-072834
Predicting risk of suicidal behaviour after initiation of selective serotonin reuptake inhibitors in children, adolescents and young adults: protocol for development and validation of clinical prediction models
Abstract
Introduction: There is concern regarding suicidal behaviour risk during selective serotonin reuptake inhibitor (SSRI) treatment among the young. A clinically useful model for predicting suicidal behaviour risk should have high predictive performance in terms of discrimination and calibration; transparency and ease of implementation are desirable.
Methods and analysis: Using Swedish national registers, we will identify individuals initiating an SSRI aged 8-24 years 2007-2020. We will develop: (A) a model based on a broad set of predictors, and (B) a model based on a restricted set of predictors. For the broad predictor model, we will consider an ensemble of four base models: XGBoost (XG), neural net (NN), elastic net logistic regression (EN) and support vector machine (SVM). The predictors with the greatest contribution to predictive performance in the base models will be determined. For the restricted predictor model, clinical input will be used to select predictors based on the top predictors in the broad model, and inputted in each of the XG, NN, EN and SVM models. If any show superiority in predictive performance as defined by the area under the receiver-operator curve, this model will be selected as the final model; otherwise, the EN model will be selected. The training and testing samples will consist of data from 2007 to 2017 and from 2018 to 2020, respectively. We will additionally assess the final model performance in individuals receiving a depression diagnosis within 90 days before SSRI initiation.The aims are to (A) develop a model predicting suicidal behaviour risk after SSRI initiation among children and youths, using machine learning methods, and (B) develop a model with a restricted set of predictors, favouring transparency and scalability.
Ethics and dissemination: The research is approved by the Swedish Ethical Review Authority (2020-06540). We will disseminate findings by publishing in peer-reviewed open-access journals, and presenting at international conferences.
Keywords: Child & adolescent psychiatry; MENTAL HEALTH; REGISTRIES; Risk Factors; Suicide & self-harm.
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
Selective serotonin reuptake inhibitors and suicidal behaviour: a population-based cohort study.Neuropsychopharmacology. 2022 Mar;47(4):817-823. doi: 10.1038/s41386-021-01179-z. Epub 2021 Sep 24. Neuropsychopharmacology. 2022. PMID: 34561608 Free PMC article.
-
[Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].Encephale. 2005 May-Jun;31(3):309-16. doi: 10.1016/s0013-7006(05)82395-4. Encephale. 2005. PMID: 16142045 French.
-
Predicting suicide attempt or suicide death following a visit to psychiatric specialty care: A machine learning study using Swedish national registry data.PLoS Med. 2020 Nov 6;17(11):e1003416. doi: 10.1371/journal.pmed.1003416. eCollection 2020 Nov. PLoS Med. 2020. PMID: 33156863 Free PMC article.
-
Use of selective serotonin reuptake inhibitors in children and adolescents.Drug Saf. 2004;27(13):991-1000. doi: 10.2165/00002018-200427130-00002. Drug Saf. 2004. PMID: 15471506 Review.
-
[SSRIs (selective serotonin reuptake inhibitors) and suicidality in adults, adolescents and children].Tijdschr Psychiatr. 2009;51(6):387-93. Tijdschr Psychiatr. 2009. PMID: 19517368 Review. Dutch.
Cited by
-
Trends in research on novel antidepressant treatments.Front Pharmacol. 2025 Jan 27;16:1544795. doi: 10.3389/fphar.2025.1544795. eCollection 2025. Front Pharmacol. 2025. PMID: 39931695 Free PMC article. Review.
References
-
- Pratt LA, Brody DJ, Gu Q. Antidepressant use among persons aged 12 and over:united states,2011-2014. NCHS Data Brief 2017:1–8. - PubMed
-
- Abbing-Karahagopian V, Huerta C, Souverein PC, et al. . Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications. Eur J Clin Pharmacol 2014;70:849–57. 10.1007/s00228-014-1676-z - DOI - PubMed
-
- Läkemedelsverket . Depression, Ångestsyndrom och Tvångssyndrom Hos barn och Vuxna - Behandlingsrekommendation. Information Från Läkemedelsverket 2016;27:26–59.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials